A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93
| Autor: | Ute-Susann Albert, B. Conrad, Walter Jonat, Sibylle Loibl, Erika Graf, Martin Schumacher, Wolfgang Eiermann, Manfred Kaufmann, Günther Gademann, Gunter von Minckwitz, M. Geberth, S. Vescia |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Oncology
Adult Cancer Research medicine.medical_specialty Cyclophosphamide medicine.medical_treatment Breast Neoplasms Disease-Free Survival Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Prospective Studies Prospective cohort study Gynecology Chemotherapy business.industry Hazard ratio Goserelin Cancer medicine.disease Treatment Outcome Premenopause Lymphatic Metastasis Patient Compliance Female business medicine.drug Epirubicin Follow-Up Studies |
| Zdroj: | European journal of cancer (Oxford, England : 1990). 43(16) |
| ISSN: | 0959-8049 |
| Popis: | GABG-IV B-93 is a prospective, randomised study comparing goserelin (n=384) with no further treatment (n=392) in hormone receptor (HR)-negative breast cancer patients (n=465) after 3 cycles cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for patients with 0-3 positive lymph nodes (LN) or 4 cycles epirubicin, cyclophosphamide (EC) followed by 3 cycles CMF for patients with 4-9 positive LN. After completion of the ZEBRA trial the study was amended to enrol also HR-positive patients with 1-9+LN (n=311). After a median follow-up of 4.7 years neither HR-negative nor HR-positive patients showed a benefit for goserelin. The adjusted estimated hazard ratio for event-free survival in HR-negative patients was 1.01 (goserelin versus control, 95% confidence interval [CI] 0.72-1.42, P=0.97) and 0.77 in HR-positive patients (95% CI 0.47-1.24, P=0.27). These results do not support the general use of goserelin after adjuvant chemotherapy in this group of premenopausal patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect